A new drug, dubbed by some as a female version of Viagra, has just been approved by the FDA to treat sexual desire in women with HSDD, an unexplained form of low libido.
FRIDAY, June 21, 2019 -- The U.S. Food and Drug Administration on Friday gave its approval to Vyleesi, the secondIn a news release, the FDA said that Vyleesi is a drug that would be administered by injection prior to havingIt's been specifically approved for premenopausal women with a condition known as acquired, generalized hypoactive sexual desire disorder .
"Today's approval provides women with another treatment option for this condition," Hylton said in the news release. Instead, women with HSDD have"previously experienced no problems with sexual desire," the FDA said."Generalized HSDD refers to HSDD that occurs regardless of the type of sexual activity, situation or partner."
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Vyleesi: New drug for women with low sex drive gets FDA approvalThe FDA has approved a new medication that will boost libido in women with low sexual desire, so that they too can have an enjoyable sex life.
Read more »
Palatin's stock rockets after FDA OK to market sexual desire disorder treatmentShares of Palatin Technologies Inc. rocketed 27% in very active premarket trading Monday, after a positive Food and Drug Administration decision on AMAG...
Read more »
Vyleesi: New drug for women with low sex drive gets FDA approvalThe FDA has approved a new medication that will boost libido in women with low sexual desire, so that they too can have an enjoyable sex life.
Read more »
What to Know About Vyleesi, the New Libido-Boosting Drug for WomenDoes Vyleesi Have Side Effects? Inside the New Libido-Boosting Drug for Women
Read more »
Palatin's stock rockets after FDA OK to market sexual desire disorder treatmentShares of Palatin Technologies Inc. rocketed 27% in very active premarket trading Monday, after a positive Food and Drug Administration decision on AMAG...
Read more »
Oklahoma judge approves Teva's $85 million opioid settlementAn Oklahoma judge on Monday approved a revised $85 million (£66.7 million) settl...
Read more »